zurück

Avapritinib (new indication: systemic mastocytosis, ≥ 1 prior therapies)

 

Subject:

  • Active Substance: Avapritinib
  • Name: Ayvakyt®
  • Therapeutic area: Systemic mastocytosis
  • Pharmaceutical company: Blueprint Medicines (Germany) GmbH

 

Time table:

  • Start: 01.04.2022
  • Final decision by G-BA: 15.09.2022

 

Final decision:

  • Hint for a non-quantifiable additional benefit